9 Osteogenesis Imperfecta Clinical Trials in Hackensack, NJ (2026)

Q: How do I join a clinical trial in Hackensack?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in Hackensack

NCT02848274Recruiting

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various ins...

Hackensack, NJ2,000 participantsStanford University

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

Hackensack, NJ316 participantsTaiho Oncology, Inc.

View Study Details

NCT03802695Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transpla...

Hackensack, NJ300 participantsOrca Biosystems, Inc.

View Study Details

NCT06714591Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia....

Hackensack, NJ120 participantsSystImmune Inc.

View Study Details

NCT06419634Recruiting

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine an...

Hackensack, NJ105 participantsBristol-Myers Squibb

View Study Details

NCT06456463Recruiting

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azaci...

Hackensack, NJ83 participantsStemline Therapeutics, Inc.

View Study Details

NCT07216443Recruiting

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for ...

Hackensack, NJ80 participantsOrca Biosystems, Inc.

View Study Details

NCT04990102Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose ...

Hackensack, NJ24 participantsGeorgetown University

View Study Details

NCT05482516Recruiting

Evaluating Novel Therapies in ctDNA Positive GI Cancers

This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic...

Hackensack, NJ20 participantsGeorgetown University

View Study Details

About Osteogenesis Imperfecta Clinical Trials in Hackensack

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 9 osteogenesis imperfecta clinical trials recruiting participants in Hackensack, NJ. These studies are seeking a combined 3,048 participants. Research is being sponsored by Stanford University, Taiho Oncology, Inc., Orca Biosystems, Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Hackensack — FAQ

Are there osteogenesis imperfecta clinical trials in Hackensack?

Yes, there are 9 osteogenesis imperfecta clinical trials currently recruiting in Hackensack, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hackensack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hackensack research site will contact you about next steps.

Are clinical trials in Hackensack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hackensack studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 9 active trials in Hackensack are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated July 13, 2026 from ClinicalTrials.gov